Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

Tsé C, Gauchez AS, Jacot W, Lamy PJ.

Cancer Treat Rev. 2012 Apr;38(2):133-42. doi: 10.1016/j.ctrv.2011.03.008. Epub 2011 May 5. Review. Erratum in: Cancer Treat Rev. 2013 Nov;39(7):831.


Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA.

J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333.


Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V.

Br J Cancer. 2012 Sep 4;107(6):956-60. doi: 10.1038/bjc.2012.353. Epub 2012 Aug 14.


Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V.

Breast Cancer Res Treat. 2010 Sep;123(2):437-45. doi: 10.1007/s10549-010-1030-9. Epub 2010 Jul 10.


Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

Lee CK, Davies L, Gebski VJ, Lord SJ, Di Leo A, Johnston S, Geyer C Jr, Cameron D, Press MF, Ellis C, Loi S, Marschner I, Simes J, de Souza P.

J Clin Oncol. 2016 Mar 20;34(9):936-44. doi: 10.1200/JCO.2015.62.4767. Epub 2016 Jan 25.


Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.

Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA.

Int J Oncol. 2009 Dec;35(6):1369-76.


Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.

Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8.


Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J.

Cancer Res. 2001 Jun 15;61(12):4744-9.


Prospect for anti-HER2 receptor therapy in breast cancer.

Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M.

Anticancer Res. 2006 Jan-Feb;26(1B):463-70. Review.


Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.

Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, Ferreira F.

Oncotarget. 2016 Apr 5;7(14):17314-26. doi: 10.18632/oncotarget.7551.


Prospect for anti-her2 receptor therapy in breast cancer.

Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M.

Anticancer Res. 2006 Jan-Feb;26(1B):715-22. Review.


The extracellular domain of Her2 in serum as a biomarker of breast cancer.

Perrier A, Gligorov J, Lefèvre G, Boissan M.

Lab Invest. 2018 Feb 28. doi: 10.1038/s41374-018-0033-8. [Epub ahead of print] Review.


Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.

Recupero D, Daniele L, Marchiò C, Molinaro L, Castellano I, Cassoni P, Righi A, Montemurro F, Sismondi P, Biglia N, Viale G, Risio M, Sapino A.

J Pathol. 2013 Feb;229(3):390-9. doi: 10.1002/path.4074. Epub 2012 Dec 13.


Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.

Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF.

Breast Cancer Res Treat. 2009 Apr;114(3):503-11. doi: 10.1007/s10549-008-0033-2. Epub 2008 Apr 25.


Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.


Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.

Stemmler HJ, Stieber P, Lässig D, Heinemann V.

Onkologie. 2005 Feb;28(2):95-7. Epub 2005 Feb 3.


Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.


Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.

Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL, Robertson JF.

Breast Cancer Res. 2007;9(6):R75.


Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J.

Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31.

Supplemental Content

Support Center